Abstracts tagged "Mesenchymal stem cells"

Abstract Number: 0861 • ACR Convergence 2024
Stem Cell Function and Capsule Tissue Composition Are Associated with Symptoms, Joint Range of Motion and Radiographic Severity in People with Knee Osteoarthritis
T Mark Campbell¹, Robert Feibel², Jeff Dilworth³, Odette Laneuville⁴ and Guy Trudel⁵, ¹Bruyère Research Institute, Ottawa, ON, Canada, ²The Ottawa Hospital, Ottawa, ON, Canada, ³University of Wisconsin, Madison, WI, ⁴University of Ottawa, Ottawa, ON, Canada, ⁵Ottawa Hospital Research Institute, Ottawa, ON, Canada
Background/Purpose: Osteoarthritis is a common and debilitating condition without cure. Increased OA severity is associated with lost range of motion (ROM) in the affected joint.…
Abstract Number: 1990 • ACR Convergence 2024
Human Umbilical Cord Mesenchymal Stem Cell-derived Microvesicles Alleviate Pulmonary Fibrosis by Inhibiting Monocyte-macrophage Migration Through ERK1/2 Signaling-mediated Suppression of CCL2 Expression
Xiuping Liang, West China Hospital, Sichuan University, Cheng Du Shi, Sichuan, China
Background/Purpose: Pulmonary fibrosis (PF) is a disease with high morbidity and mortality rates, but effective treatment options extremely limited. Mesenchymal stem cells (MSCs) and their…
Abstract Number: 2271 • ACR Convergence 2024
Intra-Articular Injection of Human Bone Marrow-Derived Mesenchymal Stem Cells in Knee Osteoarthritis: A Randomized, Double-Blind, Controlled Trial
Jennifer Lee¹ and Ji Hyeon Ju², ¹seoul st mary's hospital, Seoul, South Korea, ²Seoul St MAry's hospital, Seoul, Republic of Korea
Background/Purpose: To assess the impact of a single intra-articular (IA) injection of bone marrow-derived mesenchymal stem cells (BM-MSCs) in patients with knee osteoarthritis (OA).Methods: This…
Abstract Number: 2290 • ACR Convergence 2024
Umbilical Cord-derived Mesenchymal Stem Cells Suppress Sjogren’s Syndrome Pathology
Yukitomo Hagiwara¹, Goh Murayama², Taiga Kuga², Yujin Nishioka², Takumi Saito², Yu Yamaji², Tomoko Miyashita², Makio Kusaoi³, Ken Yamaji² and Naoto Tamura², ¹Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan, ²Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ³Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Bunkyo, Tokyo, Japan
Background/Purpose: Primary Sjögren's syndrome (pSS) is characterized by lymphocytic infiltration of the salivary and lacrimal glands, leading to functional loss and gradually causing dry mouth…
Abstract Number: 0277 • ACR Convergence 2024
Mesenchymal Stem Cells Derived from Human Bone Marrow Ameliorate Monosodium Urate Crystal-induced Inflammation
Jennifer Lee¹ and Ah Young Choi², ¹seoul st mary's hospital, Seoul, South Korea, ²The Cactholic University of Korea, Seoul, Republic of Korea
Background/Purpose: Mesenchymal stem cells (MSCs) have anti-inflammatory properties and have been implicated in several inflammatory diseases. Acute gout is initiated by IL-1β produced by monosodium…
Abstract Number: 0534 • ACR Convergence 2024
Patient Reported Outcomes and Disease Activity from a Phase 1 Double-Blind Randomized Clinical Trial of Allogeneic Mesenchymal Stem Cells in Early Rheumatoid Arthritis
Alexandre Matar¹, Maya Breitman², Tracey Bonfield³, Maricela Haghiac⁴, Jane Reese³, Emma Barnboym⁵, Steven Lewis⁶, Hillard Lazarus⁷ and Nora Singer⁸, ¹MetroHealth, Westlake, OH, ²MetroHealth Medical Center,Case Western Reserve University School of Medicine, Cleveland, OH, ³Case Western Reserve University, Cleveland, OH, ⁴Metrohealth Medical Center, Cleveland, OH, ⁵The MetroHealth System, Cleveland, OH, ⁶Case Western University, MetroHealth, Cleveland, OH, ⁷Case Western Reserve University/University Hospitals, Cleveland, OH, ⁸MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH
Background/Purpose: Mesenchymal stem (stromal) cells (MSCs) constitute an emerging therapeutic strategy for several human diseases. Small non-randomized studies have shown that MSCs may be a…
Abstract Number: 0871 • ACR Convergence 2023
Mitochondrial Transfer Functionally Restores the Human Osteoarthritis (OA) Chondrocyte, Is Protective Against Oxidative Stress and Improves OA in a Clinical Model of Disease
Fernando Figueroa¹, Angela Court², Patricia Luz Crawford², Ana Maria Vega Letter², Francesca Velarde², Cynthia Garcia² and Maroun Khoury², ¹IMPACT, Santiago de Chile, Chile, ²IMPACT, Santiago, Chile
Background/Purpose: Osteoarthrosis (OA) is a leading cause of pain, disability and early mortality, with no disease modifying treatments. Mitochondrial dysfunction is a known driver of…
Abstract Number: 1724 • ACR Convergence 2023
Human Embryonic Stem Cell-derived Mesenchymal Stem Cells Attenuates Experimental Pulmonary Fibrosis Through Mitochondria Transfer Mediated Anti-apoptotic and Immunomodulatory Effects
Hanna Lee¹, Suhee Kim², Mingyo Kim², Ok-Yi Jeong³ and Sang-Il Lee², ¹Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Changwon, South Korea, ²Department of Internal Medicine and Institute of Health Science, Gyeongsang National University School of Medicine and Hospital, JinJu, South Korea, ³Division of Rheumatology, Department of Internal Medicine and Institute of Health Science, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju, South Korea
Background/Purpose: Interstitial lung disease (ILD) is a serious condition characterized by inflammation and fibrosis in the lung interstitium. The important subtypes of ILD include idiopathic…
Abstract Number: 1991 • ACR Convergence 2023
Therapeutic Efficacy of Intra Articular Injection of Human Bone Marrow Derived Mesenchymal Stem Cells in Knee Osteoarthritis; Randomized, Double-blind, Placebo-controlled Clinical Trial
Ji Won Yang, Bong-Woo Lee, Jennifer Lee and Ji Hyeon Ju, Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea
Background/Purpose: Osteoarthritis (OA) is severe and intractable musculoskeletal disease that eventually leads to joint failure and pain due to inflammation and joint injury. Mesenchymal stem…
Abstract Number: 2496 • ACR Convergence 2023
HXB-319, a New Generation Mesenchymal Stromal Cell (MSC) Therapy, Alleviates Neutrophilic Inflammation, and End-organ Damage in Pulmonary Renal Syndromes by Inducing FoxP3+ Tregs, and by Promoting TNFα-stimulated gene-6 (TSG-6) over Expression
Hulya Bukulmez¹, Adrienne Dennis¹, Jane Reese-Koc², Scott Sieg² and Steven Emancipator², ¹MetroHealth Medical Center, Department of Pediatrics, Cleveland, OH, ²Case Western Reserve University, Cleveland, OH
Background/Purpose: Mesenchymal stromal cells (MSCs) have been shown to be safe therapies in more than 100 human clinical trials. However, MSCs clinical efficacy is variable,…
Abstract Number: 0030 • ACR Convergence 2022
Fluidic Shear Stress Reduces TNFα-mediated Cartilage Damage in a 3D Model of Degenerative Joint Disease
Alexandra Damerau¹, Duc Ha Do Nguyen¹, Christina Lubahn¹, Thomas Leeuw², Timo Gaber³ and Frank Buttgereit³, ¹Charité-Universitätsmedizin Berlin, Berlin, Germany, ²Sanofi-Aventis Deutschland GmbH, Frankfurt, Germany, ³Charité Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin / DRFZ Berlin, Berlin, Germany
Background/Purpose: Degenerative joint diseases such as osteoarthritis (OA) ultimately result in the breakdown of cartilage. The exact underlying mechanisms of cause and progression of OA…
Abstract Number: 1369 • ACR Convergence 2021
Adipose Tissue-Derived Stromal Vascular Fraction Plus Fat Grafts for Hand Therapy in Patients with Systemic Sclerosis. a Randomized Controlled Clinical Trial
Martín Iglesias¹, Iván Torre-Villalvazo¹, Armando Tovar-Palacio¹, Alejandro Zentella-Dehesa¹, Patricia Butrón-Gandarillas¹, Marta Durand-Carbajal¹, Erik Torre-Anaya², Martha Guevara² and Tatiana Rodriguez-Reyna², ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
Background/Purpose: Adipose tissue-derived Stromal Vascular Fraction (ADSVF) has been proposed as regenerative treatment for hand deformities and digital ulcer healing in patients with Systemic Sclerosis…
Abstract Number: 1440 • ACR Convergence 2021
Targeting Endogenous Mesenchymal Stromal Cell Response to Interferong in Sjӧgren’s Syndrome
Sara McCoy, Ilya Gurevic, Maxwell Parker and Jacques Galipeau, University of Wisconsin, Madison, WI
Background/Purpose: Sjӧgren’s syndrome (SS) is a systemic autoimmune disease that is associated with a lymphoma risk 14-fold that of the general population. Greater focal lymphocytic…
Abstract Number: 1502 • ACR Convergence 2021
Longitudinal Changes in B Cell Subsets in Patients in the Mesenchymal Stromal Cell Trial in Lupus: Analysis of the First Cohort
Diane Kamen¹, S Sam Lim², Scott Jenks³, Regina Bugrovosky³, Aisha Hill³, Chungwen Wei³, Cristina Drenkard³, Kenneth Kalunian⁴, Ummara Shah⁵, Mariko Ishimori⁶, Rosalind Ramsey-Goldman⁷, Saira Sheikh⁸, Mary Alison Mahieu⁷, Daniel Wallace⁹, Ellen Goldmuntz¹⁰ and Gary Gilkeson¹, ¹Medical University of South Carolina, Charleston, SC, ²Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA, ³Emory University, Atlanta, GA, ⁴UC San Diego, La Jolla, CA, ⁵University of Rochester, Rochester, NY, ⁶Cedars-Sinai Health System, Los Angeles, CA, ⁷Northwestern University, Chicago, IL, ⁸University of North Carolina, Chapel Hill, NC, ⁹Attune Health, Beverly Hills, CA, ¹⁰National Institutes of Health, Bethesda, MD
Background/Purpose: Recent advances allow expanded identification of B cell subtypes of pathogenic potential in lupus. Of particular interest are IgD- CD27- double negative (DN2) B…
Abstract Number: 1709 • ACR Convergence 2021
Long-term Safety of a Single Infusion of Human Umbilical Cord Blood-derived Mesenchymal Stem Cell Therapy in Rheumatoid Arthritis: The 5-year Follow-up of the Phase I Clinical Trial
Min Jung Kim¹, Eun Hye Park² and Kichul Shin³, ¹Seoul Metropolitan Government–Seoul National University Boramae Medical Center, Seoul, Republic of Korea, ²Chung-Ang University Hospital, Seoul, Republic of Korea, ³Seoul Metropolitan Government- Seoul National University Boramae Medical Center, Seoul, Republic of Korea
Background/Purpose: Mesenchymal stem cell (MSC) therapy represents a promise for the treatment of autoimmune diseases due to its potent immunomodulatory effect. We investigated the long-term…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].